Akos Czibere

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 564 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Jennifer K. Litton, Sara A. Hurvitz, Lida A. Mina et al. · Annals of Oncology · 2020 · 394 citations · Full text

Medicine, Oncology, Pharmacology +14

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti et al. · The Lancet Oncology · 2021 · 277 citations · Full text

Medicine, Oncology, Pharmacology +16

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

Thomas Schroeder, Akos Czibere, Uwe Platzbecker et al. · Leukemia · 2013 · 222 citations

Medicine, Hematology, Oncology +16

Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group

Thomas Schroeder, Elena Rachlis, Gesine Bug et al. · Biology of Blood and Marrow Transplantation · 2014 · 202 citations · Full text

Medicine, Hematology, Pharmacotherapy +17